Skip Ribbon Commands
Skip to main content

Assoc Prof Chew Valerie

Assoc Prof Chew Valerie

Profile

​Dr. Valerie Chew is a Principal Investigator in Translational Immunology Institute (TII), SingHealth-DukeNUS and an Associate Professor in Duke-NUS Medical School, Singapore. Her research delves into deciphering the intricate immune landscape and crosstalk within the tumor microenvironment of hepatocellular carcinoma (HCC), with a keen focus on uncovering biomarkers and therapeutic avenues.

Education

  • ​Doctor of Philosophy- Immunology (Integrative Sciences & Engineering), National University of Singapore (NUS), 2008
  • Bachelor of Science (Pharmacy), First class honours, NUS, 2003

Professional Appointments and Committee Memberships

  • Principal Investigator, Translational Immunology Institute (TII), SingHealth (Jul 2016 – Present)
  • Associate Professor, Duke-NUS Medical School (Jul 2024 – Present)
  • Governance-Council Member International Liver Cancer Association (ILCA) (2021 – Present)
  • Secretary, Singaporean Society of Immunology (SgSI) (2023 – Present)
  • Advisory Board, Nature reviews Gastroenterology & Hepatology (2024 – Present)
  • Associate Editor, npj Precision Oncology (2024 – Present)
  • Editorial board, Hepatology Communications (2023 – Present)
  • Associate Editor, Liver Cancer (2024 – Present)

Awards

  • ​Gilead Sciences Research Scholars Program in Liver Disease – Asia, 2021
  • Interstellar Initiative New York Academy of Sciences. Outstanding Early Career Investigator Team Presentation in Cancer, 2017.
  • Best of young SingHealth and Duke-NUS Scientists, 2016.
  • A*STAR JCO Young Research Collaborative Grant Award, 2012.

Research Interests

  • ​Tumor immunology 
  • Hepatocellular carcinoma

Publications and Research Trials

*As corresponding author:

J Chen, NA Kaya, Y Zhang, RI Kendarsari, et al V Chew et al PKH Chow. A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and ‘bad apple’ effect on clinical trajectory. J Hepatology, 2024. https://doi.org/10.1016/j.jhep.2024.05.017.

BC Narmada, A Khakpoor, N Shirgaonkar et al V Chew et al SG Lim and R DasGupta. Single cell landscape of functionally cured Chronic Hepatitis B patients reveals activation of innate and an altered CD4-CTL-driven adaptive immunity. J Hepatology, 2024. 
https://doi.org/10.1016/j.jhep.2024.02.017. 

HD Lee, SY Jung, et al V Chew et al CH Yoo. Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial. Nature Medicine, 2024. https://doi.org/10.1038/s41591-024-02824-y.

S Ma & V Chew*. Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology, 2023; 10.1097.

V Chew*. Unveiling the hidden battlefield: dissecting the invasive zone in liver cancer. Cell Research, 2023; 33, 651–652.

MJY Reolo, M Otsuka, et al V Chew*. CD38 marks the exhausted CD8+ tissue-resident memory T cells in hepatocellular carcinoma. Front.Immunol, 2023; 14, 1182016.

YH Lee, S Chuah, et al V Chew*. IFNγ− IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. Cancer Letters, 2023; 215977.

S Chuah, J Lee, Y Song, et al D Tai, V Chew*. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J Hepatology, 2022.

P Nguyen, M Wasser et al. V Chew*.  Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nature Com, 2022.

S Suthen, CJ Lim, P Nguyen et al. V Chew*. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma. Hepatology, 2022.

S Chuah and V Chew*. Immune implication of an autophagy-related prognostic signature in uveal melanoma. Bioscience reports, 2021. Vol 41 (8), BSR20211098.

P Nguyen, S Ma et al P Chow, W Zhai and V Chew*. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nature Com, 2021; 12, 227.

CJ Lim et al. V Chew*. Immunological hallmarks for clinical response to BCG in bladder cancer. Front. Immunol, 2021. https://doi.org/10.3389/fimmu.2020.615091.

CJ Lim and V Chew*. Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Semin Liver Dis, 2020. 

YH Lee, D Tai, C Yip, SP Choo and V Chew*. Combinational immunotherapy for Hepatocellular carcinoma (HCC): Radiotherapy, immune checkpoint blockade and beyond. Front. Immunol, 2020; Sep 30;11:568759.  doi: 10.3389/fimmu.2020.568759.

S Chuah and V Chew*. High-dimensional immune-profiling in cancer- implications for immunotherapy. Journal for ImmunoTherapy of Cancer (JITC), 2020;8:e000363. doi: 10.1136/jitc-2019-000363. 

D Tai, SP Choo and V Chew*. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019; 11(12), 1926.  

CJ Lim, YH Lee, et al. V Chew*. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut, 2019; May;68(5):916-927.

V Chew*, YH Lee, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut, 2019; 68(2): 335-346. 

V Chew*, L Lai, L Pan, CJ Lim, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proceedings of the National Academy of Sciences, 2017; 114(29): E5900-E5909.

M Garnelo, A Tan, et al. V Chew*. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut, 2017; 66(2): 342-351.

Research Trials

  • Updated on